LabyRx Immuno-Oncology focuses on developing innovative therapies that harness the body's immune system to combat cancer. Their pipeline includes a range of products designed to enhance immune responses against tumors, utilizing advanced techniques to target specific cancer cells while minimizing damage to healthy tissues. The company emphasizes the importance of personalized medicine, tailoring treatments to individual patient profiles to improve efficacy and reduce side effects.

The technologies employed by LabyRx include proprietary platforms that facilitate the identification and validation of novel immunotherapeutic targets. Their research leverages cutting-edge methodologies in immunology and molecular biology to create therapies that can effectively stimulate the immune system. By integrating these technologies, LabyRx aims to advance the field of immuno-oncology, providing new hope for patients facing various types of cancer through more effective and targeted treatment options.

United States

LabyRx Immuno-Oncology is a bio-medical company focused on developing a comprehensive platform for treating adenocarcinomas, a class of glandular-related tumors that represent approximately 40% of worldwide cancer cases and 50% of treatment-related spending.  Based upon our scientists' discovery and ongoing research into the unique adenocarcinoma target – Labyrinthin – the Company aims to advance novel cancer therapeutic technologies that improve treatment processes.  

The team comprise renown scientists in the United States and Hong Kong working towards cancer therapeutics and diagnostics.

LabyRx Immuno-Oncology

Company Details